Methods and compositions for suppressing ige-mediated anaphylaxis

Abstract

Methods for suppressing IgE-mediated anaphylaxis are provided herein, which include administering to a person in need thereof a combination of at least two therapeutic agents selected from the group consisting of an antihistamine, one or more beta-adrenergic agonists, and one or more tyrosine kinase antagonists. Also provided herein are methods of suppressing IgE-mediated anaphylaxis associated with immunotherapeutic desensitization of a subject, and pharmaceutical compositions for suppressing IgE-mediated anaphylaxis.

1 . A method of suppressing IgE-mediated anaphylaxis comprising administering to a subject in need thereof a combination of least two therapeutic agents selected from the group consisting of imatinib, fostamatinib, and triprolidine. 
     
     
         2 . The method of  claim 1 , further comprising administering an antigen or an antibody selected from the group consisting of an anti-IgE monoclonal antibody, an anti-Fc epsilon receptor I alpha (FcεRIα) monoclonal antibody, and combinations thereof. 
     
     
         3 - 5 . (canceled) 
     
     
         6 . The method of  claim 2 , further comprising administering a corticosteroid. 
     
     
         7 . The method of  claim 6 , wherein the corticosteroid comprises dexamethasone. 
     
     
         8 . The method of  claim 2 , wherein the combination of at least two therapeutic agents is administered prior to administering the antigen or antibody. 
     
     
         9 . The method of  claim 1 , wherein the at least two therapeutic agents are administered simultaneously or consecutively. 
     
     
         10 . A method of suppressing IgE-mediated anaphylaxis associated with immunotherapeutic desensitization of a subject in need thereof, the method comprising:
 a) treating the subject with a combination of at least two therapeutic agents selected from the group consisting of imatinib, fostamatinib, and triprolidine; and   b) administering to the subject an antigen or an antibody selected from the group consisting of an anti-IgE monoclonal antibody, an anti-Fc epsilon receptor I alpha (FcεRIα) monoclonal antibody, and combinations thereof,   wherein the treating step (a) suppresses IgE-mediated anaphylaxis in the subject.   
     
     
         11 . The method of  claim 10 , further comprising administering a corticosteroid. 
     
     
         12 . The method of  claim 11 , wherein the corticosteroid comprises dexamethasone. 
     
     
         13 . The method of  claim 11 , wherein the corticosteroid is administered prior to administering the antigen or antibody. 
     
     
         14 - 16 . (canceled) 
     
     
         17 . A pharmaceutical composition for suppressing IgE-mediated anaphylaxis comprising:
 (a) a safe and effective amount of at least two therapeutic agents selected from the group consisting of triprolidine, imatinib, and fostamatinib; and   (b) one or more pharmaceutically-acceptable excipients.   
     
     
         18 . The pharmaceutical composition of  claim 17 , further comprising a corticosteroid. 
     
     
         19 . The pharmaceutical composition of  claim 18 , wherein the corticosteroid comprises dexamethasone. 
     
     
         20 . The pharmaceutical composition of  claim 17 , further comprising an antigen or an antibody selected from the group consisting of an anti-IgE monoclonal antibody, an anti-Fc epsilon receptor I alpha (FcεRIα) monoclonal antibody, and combinations thereof. 
     
     
         21 - 22 . (canceled) 
     
     
         23 . The pharmaceutical composition of  claim 17 , wherein the at least two therapeutic agents comprise triprolidine, fostamatinib, and imatinib. 
     
     
         24 - 26 . (canceled) 
     
     
         27 . The method of  claim 1 , wherein the combination of at least two therapeutic agents consists of imatinib and fostamatinib. 
     
     
         28 . The method of  claim 1 , wherein the combination of at least two therapeutic agents consists of imatinib and triprolidine. 
     
     
         29 . The method of  claim 1 , wherein the combination of at least two therapeutic agents consists of fostamatinib and triprolidine. 
     
     
         30 . The method of  claim 1 , wherein the combination of at least two therapeutic agents consists of imatinib, fostamatinib, and triprolidine.